A New Leader Joins the Fight Against Cancer
ViroMissile, Inc. has announced the appointment of Michael G. Wood as their new Chief Business Officer. This strategic move is significant for the company, which is pioneering a novel approach to cancer treatment using viruses.
Wood's Role and Expertise
Wood's responsibilities will include:
- Driving company growth
- Securing funding for projects
- Negotiating key partnerships
Wood brings a wealth of experience in biotechnology and pharmaceuticals. His career spans:
- Launching startups
- Working with major pharmaceutical firms
- Raising millions for R&D
Prior to joining ViroMissile, Wood held key positions at OncoMyx Therapeutics and Crinetics Pharmaceuticals.
Why ViroMissile?
Wood is excited about ViroMissile's innovative approach to cancer treatment. The company's IDOV™ platform delivers viruses directly into the bloodstream, targeting tumors throughout the body. This is a breakthrough, as most current treatments struggle with metastatic tumors.
Timing is Everything
Wood's appointment comes at a crucial time. ViroMissile has just begun human trials for IDOV-immune, their flagship virus platform. Wood's experience in transitioning companies from lab to clinical trials will be invaluable.
Focus on Hard-to-Treat Cancers
ViroMissile is targeting aggressive cancers that are difficult to treat. Their goal is to use viruses not only to kill tumor cells but also to activate the immune system, potentially leading to long-lasting responses in patients with limited options.
The Perfect Fit
Wood's background in science, business, and finance makes him an ideal fit for ViroMissile. His expertise will help navigate the complexities of biotechnology and bring innovative treatments to patients in need.
